Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus rating of “Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $43.17.

A number of equities research analysts recently commented on ORKA shares. Leerink Partners assumed coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price objective on the stock. TD Cowen assumed coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research report on Monday, November 25th. Finally, Jefferies Financial Group started coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company.

Hedge Funds Weigh In On Oruka Therapeutics

A number of large investors have recently bought and sold shares of ORKA. Geode Capital Management LLC purchased a new position in shares of Oruka Therapeutics in the 3rd quarter worth $343,000. The Manufacturers Life Insurance Company purchased a new stake in Oruka Therapeutics during the third quarter worth approximately $1,037,000. Wellington Management Group LLP acquired a new stake in shares of Oruka Therapeutics in the third quarter worth $2,013,000. Janus Henderson Group PLC purchased a new stake in Oruka Therapeutics during the 3rd quarter worth $5,840,000. Finally, Redmile Group LLC acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at $10,091,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Stock Performance

ORKA opened at $21.73 on Monday. The stock has a market capitalization of $760.55 million, a P/E ratio of -3.47 and a beta of 0.87. Oruka Therapeutics has a one year low of $18.20 and a one year high of $53.88. The business’s fifty day moving average price is $25.60.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.